title: Perspectives and progress in development of breast cancer chemopreventive drugs.
authors.affiliation: Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: G J
authors.initials: GJ
authors.lastname: Kelloff
authors.forename: C W
authors.initials: CW
authors.lastname: Boone
authors.forename: J A
authors.initials: JA
authors.lastname: Crowell
authors.forename: S G
authors.initials: SG
authors.lastname: Nayfield
authors.forename: E T
authors.initials: ET
authors.lastname: Hawk
authors.forename: V E
authors.initials: VE
authors.lastname: Steele
authors.forename: R A
authors.initials: RA
authors.lastname: Lubet
authors.forename: C C
authors.initials: CC
authors.lastname: Sigman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000517:prevention & control*; D003687:Dehydroepiandrosterone / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D017313:Fenretinide / Q000627:therapeutic use; D006801:Humans; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004965:Estrogen Antagonists; D013629:Tamoxifen; D017313:Fenretinide; D003687:Dehydroepiandrosterone